Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ally Bridge Backs $301 Million Privatization of Luoxin Pharma

publication date: Mar 15, 2017
Shandong Luoxin Pharma of Shanghai received a $301 million management-led privatization offer. Ally Bridge Group, which is participating in the deal, will buy 33% of the company's outstanding shares, and the company's management will purchase the rest. The offer represents a 25% premium over the previous closing price -- the stock has not been trading since early this month pending news. Luoxin offers a broad list of products, including antibiotics, anti-virals and cancer treatments. The offer prices the company at about 24 times earnings. More details....

Stock Symbol: (HK: 8058)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital